The Heart Is A Muscle Too!
The Cardiomyopathy in Duchenne muscular dystrophy

Linda Cripe MD
Professor of Pediatrics
Vice Chair of Faculty Affairs
Nationwide Children’s Hospital/The Ohio State University
Why are cardiologists interested in caring for patients with neuromuscular disorders?
The Heart is a Muscle TOO!!!
Cardiologists are interested in neuromuscular disorders

- Improve quality/duration of life of patients with:
  - Neuromuscular as well as cardiovascular disease

Many neuromuscular diseases such as DMD have an associated cardiomyopathy and vice versa
- Understanding DMD cardiomyopathy will likely improve understanding of DMD skeletal muscle disease
- This will ultimately improve duration and quality of life for our patients
Interest in DMD cardiomyopathy has experienced an exponential increase.
Hot topics in DMD cardiomyopathy

- Cardiac magnetic resonance imaging (CMR)
- New insights into DMD chest pain
- Novel treatments employing cardiac devices
- Cardiomyopathy in female carriers
Cardiac imaging is important because...

- Help us to better understand the natural history of the disease
  - As imaging modalities improve we see the disease with new eyes
    - Era of echocardiography: Cardiomyopathy not present until late teen years
    - Now with CMR: know disease present much earlier
  - Improved understanding will
    - Guide clinical care
    - Provide better clinical trial endpoints
Echocardiography has limitations

- Image quality is poor in many DMD patients (especially in non-ambulatory patients)
- Sub-optimal images result in poor clinical decision making and poor clinical trial data
Advantages
- Lack of radiation exposure
- Provides detailed information:
  - Myocardial mass
  - Volume
  - LV and RV function
  - Fibrosis quantification
  - Edema/inflammation
  - Myocardial strain

Disadvantages
- IV placement required for fibrosis quantification
- Longer scan times
- Pediatric patients are not cooperative
- Lack of global availability
A key concept in understanding DMD cardiomyopathy

Cardiomyopathy in Duchenne muscular dystrophy is characterized by extensive sub-epicardial fibrosis.
CMR has expanded our understanding of DMD cardiomyopathy

- Sub-epicardial fibrosis is easily identified easily on CMR
  - Fibrosis starts in the sub-epicardium of the basolateral or inferolateral wall and progresses to apex and then septum
  - Importantly, it is present
    - Prior to decline of LV function
    - Early in the disease
- Of note, sub-epicardial enhancement is seen in myocarditis
  - Represents inflammatory infiltrate
- Begs the question:
  - Are similar pathophysiological mechanisms at work in DMD and myocarditis?
Late gadolinium enhancement (fibrosis) in DMD Cardiomyopathy

Menon SC et al. Ped Cardiol 2014.
Natural history data (NCH)

- Fibrosis incidence (314 patients)
  - 17% <10 years
    - Youngest patient 6 years
  - 34% 10-15 years
  - 59% >15 years

  - 30% with normal cardiac function
  - 84% with abnormal cardiac function
Utilizing CMR to help us look at common problems differently - pediatric chest pain
Chest pain in the DMD patient

- FREQUENT and typically attributed to the musculoskeletal system
- Often dismissed in a pediatric ER
- Formal cardiac evaluation rarely undertaken
  - ECG is sometimes obtained
  - Troponin I (cTnI) rarely obtained
    - cTnI is a sensitive and reliable marker of cardiac muscle tissue injury
    - cTnI is normal or minimally elevated at baseline in DMD
    - Not thought to be predictive of disease progression
We have seen that too!

Our patient had elevated troponins did your patient have MRI changes?

What do you think is going on?

We had 3 patients present like that last year!

How did you treat them?

What have you noticed on follow-up?
Chest pain in the DMD patient

- Case series of 8 DMD patients (NCH; 2013-2017)
  - Acute chest pain and transient elevations of cTnI
  - Average age of 15 years (range 9-23 years)
- Clinical characteristics
  - 8/8 acute chest pain, ECG changes and elevation of cTnI
    - ECG demonstrated diffuse ST segment elevation
    - NOT a ST-elevation myocardial infarction (STEMI) pattern thus not consistent with coronary ischemia
  - 5/8 no antecedent illness
  - 3/8 concurrent illness
    - Pneumonia, gastroenteritis, and sepsis
  - 8/8 were on an ACE inhibitor
  - 5/8 were on corticosteroid
7/8 cTnI was elevated on admission and normalized within 4 days
1/8 presented with sepsis and late cTnI elevation which persisted >200 hours
  - Mean peak cTnI level of 44.1 (range 31-62 ng/ml)
CMR findings for patient 6

baseline

acute phase of event

follow-up
Serial LVEF assessment by CMR

Timing of Left Ventricular Ejection Fraction Assessment

Baseline | ACP Presentation | Short Term | Long Term
Serial LGE (fibrosis) evaluation by CMR

Late Gadolinium Enhancement (%) Compared to Normal Left Ventricular Mass

Timing of Late Gadolinium Enhancement Assessment

Baseline | ACP Presentation | Short Term | Long Term
Clinical course

• 4/8 patients underwent coronary artery evaluation
  – 2/4 cardiac CT and 2/4 cardiac cath
  – NO coronary abnormalities identified
• All viral studies were negative
• Patients received supportive care with traditional cardiac medications
• Ongoing follow-up continues on all patients
Chest pain discussion

• We hypothesize that progression of DMD associated cardiomyopathy results in part from episodic myocardial injury rather than exclusively from continuous ongoing injury
  – Silent and recurrent events lead to cumulative injury
  – Process similar to that which occurs in skeletal muscle
  – Suggests a step wise model of disease progression as opposed to a linear one

• Unknown if there could there be external triggers
  – Viral infection
  – Physiological stress
  – Other intercurrent illness

• Role of inflammatory cytokines given that 3/8 patients presented with infection
Suspected acute myocardial infarction in a dystrophin-deficient dog

Sarah Morar Schneider a,1, Amanda Erickson Coleman b,1,2, Lee-Jae Guo c,d, Sandra Tou b, Bruce W. Keene b, Joe N. Kornegay a,c,d,e,f,*

• 7 mo old GRMD dog with acute onset of cardiac decompensation consistent with a myocardial infarction
• Died suddenly at 45 months with induction of anesthesia
  – Serum biomarkers, including cTnI were markedly increased
  – Echo evidence of regional wall dysfunction
  – Sub-epicardial myocardial fibrosis and decreased LVEF noted on CMR
  – Sub-epicardial fibrosis noted on pathology

Cardiac devices in the treatment of Duchenne muscular dystrophy

Implantable cardioverter defibrillator (ICD)

Heart

Leads

ICD

Pulse generator

Left ventricular assist device
ICD) Implantable cardioverter defibrillator

- Battery-powered device placed under the skin
  - Monitors heart rate
  - Provides a shock when sustained ventricular tachycardia or fibrillation is detected
- Newer-generation ICDs
  - Dual pacemaker function
  - Pacemaker feature paces the heart when bradycardia is detected
ICDs are great when needed, but come with complications

Prevent sudden death

May cause complications
• Inappropriate shocks
• Lead dislodgement
• Lead failure
• Psychological impact
What are the indications for ICD placement in DMD?

• NO significant data for ICD placement in patients with DMD

• Look to other patient populations for guidance

• Several important trials conducted in adults with cardiomyopathy
  – SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial)
    • ICD therapy reduced overall mortality *for both ischemic and non-ischemic cardiomyopathy* by 23% compared to placebo

• As a result, current class I indications for ICD placement in adult cardiomyopathy are:
  • LVEF <35% and
  • NYHA functional class II or III (mild to moderate CHF)

Bardy et al. NEJM 2005;352:225
So where does that leave us….

- Individuals with cardiomyopathy are at risk of sudden cardiac death
- ICD’s prevent sudden cardiac death

Hmmmmm……..

- Pts with DMD develop cardiomyopathy
- Therefore everyone with DMD who is symptomatic with a LVEF<35% should get an ICD
- Or should they…..?

- What is the incidence of sudden cardiac death in DMD?
To answer this question, we must know more about the natural history of rhythm problems in DMD.
What is the natural history of rhythm problems in DMD?

- Villa et al retrospectively reviewed 442 holters of 235 pts (2010-2014)
  - Mean age 14 ± 4 years (88% were for routine screening)

<table>
<thead>
<tr>
<th></th>
<th>EF ≥ 55%</th>
<th>EF 35-54%</th>
<th>EF &lt; 35%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients</td>
<td>184</td>
<td>46</td>
<td>5</td>
</tr>
<tr>
<td>Non-sustained VT</td>
<td>2%</td>
<td>2%</td>
<td>40%</td>
</tr>
<tr>
<td>Death</td>
<td>3 (non-cardiac)</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

- Conclusions:
  - Clinically significant holter recordings were rare in patients with LVEF >35%
  - Sudden cardiac death is also rare in DMD patients with LVEF >35%
  - Holter monitoring has highest yield in DMD patients with dysfunction

Villa et al. J Am Heart Assoc 2016; 5:e002620
What is the incidence of sudden cardiac death in DMD?

- Nationwide Children’s Hospital Sudden Cardiac Death Registry
  - International ongoing study
  - Identified 90 subjects with EF <55%
  - Average age 21 years
  - Average LVEF of 37% (range 8%-54%)
- 14/90 patients had significant arrhythmias
- 9 non sustained VT, 2 atrial tachycardia, 3 atrial flutter and 2 SVT
- 9/90 patients had ICDs implanted with 0 appropriate fires
- One ICD patient died suddenly
  - Device interrogation demonstrated no tachyarrhythmia
  - Death was likely a respiratory event

Suggests ICD placement for EF <35% may not be indicated, in contrast to adult guidelines
Mechanical Circulatory Support

- Use of a mechanical pump/s to support a weakened heart muscle.
  - Ventricular Assist Device (VAD) to assist a single weakened ventricle
  - Total Artificial Heart (TAH) to replace a failing biventricular heart
- Three indications:
  - Bridge to transplant (BTT)
  - Bridge to Recovery
  - Destination therapy (chronic therapy)

- Transplantation is not typically considered an option in DMD
  - Limited donor availability
  - Complex ethical issues
    • Patients develop progressive respiratory failure and skeletal myopathy
LVAD use in DMD

- Limited case reports in the literature regarding use of LVAD in DMD
  - Largest series (7 patients) reported by Bambino Gesu Children’s Hospital in Rome
    - 6 with DMD and 1 with β2 sarcoglycan deficit
    - Median follow-up of 21.7 months (range 3-45 months)
    - 3 non cardiac deaths

- Challenges exist for the use of LVAD devices in DMD
  - Multi-disciplinary evaluation required
  - Candidate selection critical
  - Delayed wound healing secondary to muscle wasting
  - Device placement must not disrupt diaphragm function

- Unclear if use will prolong duration and quality of life

Perri G et al J Thorac Surg 2017 Mar; 153(3) 669-674
Lastly........
Female carriers

- To date majority of carrier studies focused on cardiac manifestations
- Reported that cardiac abnormalities are not present until adulthood
  - Incidence is variable and dependent on imaging modality
    - Echocardiographic studies (8%-38%)
    - Single recent CMR study (Florian et al)
      - 36 DMD/BMD carriers (44 ± 14 years)
      - 4% had a reduced LVEF
      - 44% had evidence of fibrosis
    - Suggests that carriers may be at higher risk than previously believed

Nationwide Children’s female carrier study

- Recruitment ongoing (aim 100 carriers/50 non-carriers)
  - Functional skeletal muscle evaluation
  - Psychological evaluation
  - Cardiac evaluation (CMR and exercise testing)

<table>
<thead>
<tr>
<th></th>
<th>Carrier</th>
<th>Non-carrier</th>
</tr>
</thead>
<tbody>
<tr>
<td>Average age (yrs)</td>
<td>42 ± 8 (29-63)</td>
<td>40 ± 10 (28-65)</td>
</tr>
<tr>
<td>LVEDVi &gt; 100 ml/m²</td>
<td>3/34 (8%)</td>
<td>0/12 (0%)</td>
</tr>
<tr>
<td>(chamber enlargement)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LVEF &lt; 55%</td>
<td>5/34 (15%)</td>
<td>0/12 (0%)</td>
</tr>
<tr>
<td>Fibrosis</td>
<td>17/34 (50%)</td>
<td>0/12 (0%)</td>
</tr>
</tbody>
</table>

- These very preliminary data suggest a significant incidence of low LVEF and fibrosis
- We need to better understand the morbidity associated with carrier status
Conclusions

• The heart is an important muscle, too
• CMR is a valuable and informative tool to evaluate the cardiomyopathy in DMD
• Chest pain in the DMD patient may signal acute cardiac injury
  – cTnl levels and ECG should be obtained
• Cardiac devices have an evolving but uncertain role in management of DMD patients
• Carriers may be at elevated risk for cardiac disease
• Finally...
We can all achieve better patient outcomes with breakdown of clinical silos.
THANK YOU

O-H-I-O